This study is currently recruiting participants.
Purpose: The primary objective of this study is to demonstrate the superiority of gevokizumab (at least one of the two doses) compared to placebo in the treatment of subjects with active non-infectious intermediate, posterior, or pan- uveitis. In addition, the safety of gevokizumab will be assessed.
C. Michael Samson, MD, Uveitis Specialist
Alex Yang, Clinical Research Coordinator at (212) 979-4024
Home > Current Research > Clinical Trials in Ophthalmology >A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan-Uveitis